Regulatory status and legal considerations The legal landscape for these compounds is quite different, and understanding the regulatory environment matters for practical decision-making
Sue Down over 60 lbs
Your diabetes team will assess your individual circumstances, including HbA1c levels, weight, cardiovascular risk, and kidney function, to determine if you're suitable for this treatment
Although GLP-1RAs attenuate inflammatory signaling [105], NAD metabolism remains dynamically regulated and tissue-specific [83, 106, 109]
On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, citing no clinical need for large-scale compounding now that FDA-approved supply is stable
For many individuals, reducing excess body weight can dramatically improve overall health and quality of life